New obesity drug candidate enters first human tests
NCT ID NCT07152002
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing an experimental drug called LY4064912 in 144 healthy volunteers and people with overweight or obesity. The main goal is to check safety and how the body handles the drug, not yet to prove it works for weight loss. Participants will receive either the drug or a placebo by injection or IV infusion, and researchers will monitor side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4064912 (an experimental drug given as an injection under the skin or into a vein)
What this could lead to
If successful, this could lead to a new weight-loss treatment option for people with overweight or obesity.
What could go wrong
This is a very early Phase 1 trial focused on safety, not weight loss. The drug may cause side effects or fail to work in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Collaborative Neuroscience Network - CNS
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-••••
Contact
-
ICON Early Phase Services
RECRUITINGSan Antonio, Texas, 78209, United States
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
Contact Phone: •••-•••-••••
Contact